Fungal Infections Clinical Trials

None

UPCC 54419: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

This study enrolls subjects with relapsed or refractory CD30-positive Peripheral T-cell Lymphoma (PTCL) or Transformed Mycosis Fungoides (TMF). The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated.

A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL

Study participation involves four periods: a) Screening Period, b) Treatment Period 1, c) Washout Period, and d)Treatment Period 2. Subjects at least 21 years of age with a diagnosis of mycosis fungoides (MF) .